Literature DB >> 11605727

Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity.

E Cottone1, F Orso, N Biglia, P Sismondi, M De Bortoli.   

Abstract

Nuclear receptors regulate target gene expression in response to steroid and thyroid hormones, retinoids, vitamin D and other ligands. These ligand-dependent transcription factors function by contacting various nuclear cooperating proteins, called coactivators and corepressors, which mediate local chromatin remodeling as well as communication with the basal transcriptional apparatus. Nuclear receptors and their coregulatory proteins play a role in cancer and other diseases, one leading example being the estrogen receptor pathway in breast cancer. Coregulators are often present in limiting amounts in cell nuclei and modifications of their level of expression and/or structure lead to alterations in nuclear receptor functioning, which may be as pronounced as a complete inversion of signaling, i.e. from stimulating to repressing certain genes in response to an identical stimulus. In addition, hemizygous knock-out of certain coactivator genes has been demonstrated to produce cancer-prone phenotypes in mice. Thus, assessment of coactivator and corepressor expression and structure in tumors may turn out to be essential to determine the role of nuclear receptors in cancer and to predict prognosis and response to therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605727     DOI: 10.1177/172460080101600301

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  9 in total

1.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells.

Authors:  Steven M Townson; Kaiyan Kang; Adrian V Lee; Steffi Oesterreich
Journal:  Biochem Biophys Res Commun       Date:  2006-08-22       Impact factor: 3.575

Review 3.  Estrogen and progesterone receptors: from molecular structures to clinical targets.

Authors:  Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

4.  Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Peng Guo; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2011-03-02       Impact factor: 5.157

5.  Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP.

Authors:  Xue-Yuan Dong; Xiaoying Fu; Songqing Fan; Peng Guo; Dan Su; Jin-Tang Dong
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

6.  G0S2 is an all-trans-retinoic acid target gene.

Authors:  Sutisak Kitareewan; Steven Blumen; David Sekula; Reid P Bissonnette; William W Lamph; Qingping Cui; Robert Gallagher; Ethan Dmitrovsky
Journal:  Int J Oncol       Date:  2008-08       Impact factor: 5.650

Review 7.  Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.

Authors:  Esmael Besufikad Belachew; Dareskedar Tsehay Sewasew
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-25       Impact factor: 5.555

Review 8.  Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

Authors:  Rocío García-Becerra; Nancy Santos; Lorenza Díaz; Javier Camacho
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

9.  A neuronal-specific differentiation protein that directly modulates retinoid receptor transcriptional activation.

Authors:  Kenneth W Henry II; Michael L Spencer; Maria Theodosiou; Dingyuan Lou; Daniel J Noonan
Journal:  Nucl Recept       Date:  2003-09-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.